Background: Asthma is a common respiratory disease among both adults and children and short acting inhaled beta-2 agonists are used widely for \u27reliever\u27 bronchodilator therapy. Long acting beta-2 agonists (LABA) were introduced as prospective \u27symptom controllers\u27 in addition to inhaled corticosteroid \u27preventer\u27 therapy (ICS). In this updated review we have included studies in which patients were either not on ICS as a group, or in which some patients, but not all, were on ICS to complement previous systematic reviews of studies where LABA was given in patients uniformly receiving ICS. We have focused particularly on serious adverse events, given previous concerns about potential risks, especially of death, from regular ...
Asthmatic patients should be explained that FDA recently issued a black box warning regarding use of...
Background The safety of long-acting β 2 agonist (LABA) therapy in asthma remains controversial but ...
Background: It is unclear whether long-acting β-agonists with concomitant inhaled corticosteroids...
Asthma is a common respiratory disease among both adults and children and short acting inhaled beta-...
International audienceBACKGROUND: Although several systematic reviews investigated the safety of lon...
BACKGROUND: Poorly controlled asthma and preventable exacerbations place a significant strain on hea...
Large surveillance studies or phase IV clinical studies of long-acting β-agonists (LABA) compared wi...
BACKGROUND: Poorly controlled asthma and preventable exacerbations place a significant strain on hea...
Several studies suggested an association between the regular use of β2-agonists and asthma deaths. ...
The objective of this study was to describe risks of death and asthma outcomes with prescription of ...
The objective of this study was to describe risks of death and asthma outcomes with prescription of ...
BACKGROUND: Epidemiological evidence has suggested a link between beta2-agonists and increases in as...
Several studies suggested an association between the regular use of β 2-agonists and asthma deaths. ...
Background: Bronchiectasis is a major contributor to chronic respiratory morbidity and mortality wor...
The objective of this study was to describe risks of death and asthma outcomes with prescription of ...
Asthmatic patients should be explained that FDA recently issued a black box warning regarding use of...
Background The safety of long-acting β 2 agonist (LABA) therapy in asthma remains controversial but ...
Background: It is unclear whether long-acting β-agonists with concomitant inhaled corticosteroids...
Asthma is a common respiratory disease among both adults and children and short acting inhaled beta-...
International audienceBACKGROUND: Although several systematic reviews investigated the safety of lon...
BACKGROUND: Poorly controlled asthma and preventable exacerbations place a significant strain on hea...
Large surveillance studies or phase IV clinical studies of long-acting β-agonists (LABA) compared wi...
BACKGROUND: Poorly controlled asthma and preventable exacerbations place a significant strain on hea...
Several studies suggested an association between the regular use of β2-agonists and asthma deaths. ...
The objective of this study was to describe risks of death and asthma outcomes with prescription of ...
The objective of this study was to describe risks of death and asthma outcomes with prescription of ...
BACKGROUND: Epidemiological evidence has suggested a link between beta2-agonists and increases in as...
Several studies suggested an association between the regular use of β 2-agonists and asthma deaths. ...
Background: Bronchiectasis is a major contributor to chronic respiratory morbidity and mortality wor...
The objective of this study was to describe risks of death and asthma outcomes with prescription of ...
Asthmatic patients should be explained that FDA recently issued a black box warning regarding use of...
Background The safety of long-acting β 2 agonist (LABA) therapy in asthma remains controversial but ...
Background: It is unclear whether long-acting β-agonists with concomitant inhaled corticosteroids...